EyePoint, Ocumension expand licensing agreements in Asia
Click Here to Manage Email Alerts
EyePoint Pharmaceuticals and Ocumension Therapeutics have expanded their license agreements regarding Yutiq and Dexycu in specific Asian markets, according to a press release.
EyePoint received $9.5 million from Ocumension, which will commercialize the products under its own brand names in South Korea and other markets throughout Southeast Asia.
“We are delighted to expand our partnership with Ocumension to include the broader Asian marketplace. The payment from the expanded license agreements will support our operations and the ongoing clinical development of our pipeline, including our lead candidate, EYP-1901, a potential 6-month sustained delivery therapy for wet age-related macular degeneration,” George Elston, EyePoint chief financial officer and head of corporate development, said in the release.
EyePoint previously announced in a separate press release that it plans to file an investigational new drug application for EYP-1901 later this year.
Read more about
Click Here to Manage Email Alerts